ProCE Banner Activity

DESTINY-Breast04: Trastuzumab Deruxtecan vs Physician’s Choice of Chemotherapy for Previously Treated HER2-Low Advanced Breast Cancer

Slideset Download
Conference Coverage
Trastuzumab deruxtecan improves survival in patients with HER2 IHC1+ and IHC2+/ISH-negative advanced breast cancer.

Released: June 08, 2022

Expiration: June 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab